Medtronic (NYSE:MDT) announces positive
results from a U.S. pivotal study evaluating its MiniMed 780G Advanced
Hybrid Closed Loop insulin pump in adolescent and adult diabetics. The
results were virtually presented at the Scientific Sessions of the ADA.
The device, CE Mark’d
this week, features a default target of 100 mg/dL (with an option of
120 mg/dL), programmable insulin action time from two to eight hours and
automatic corrections every five minutes.
Average A1C levels of 7.0% with overall time in
range (70-180 mg/dL) of 75% and overall time below range (less than 70
mg/dL) of 1.8%.
Autocorrection contributed 22% of all bolus insulin.
Participants in SmartGuard (closed loop) 95% of the time.
At the default setting, mean sensor glucose was 144 mg/dL overall and 148 mg/dL overall.
No severe hypoglycemia or diabetic ketoacidosis occurred.
Time in range at the default setting was 76% overall at the 2-3 hour active insulin time (AIT) and 79% at the 2 hour AIT.
The data will support a U.S. marketing application.
https://seekingalpha.com/news/3582830-medtronic-next-gen-closed-loop-insulin-system-successful-in-u-s-trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.